Identification

Name
Dapagliflozin
Accession Number
DB06292
Type
Small Molecule
Groups
Approved
Description

Dapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014. Dapagliflozin is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Structure
Thumb
Synonyms
  • (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
External IDs
BMS 512148 / BMS-512148
Product Ingredients
IngredientUNIICASInChI Key
Dapagliflozin propanediol monohydrate887K2391VH960404-48-2GOADIQFWSVMMRJ-UPGAGZFNSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated10 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideTablet, film coated5 mgOralAstra Zeneca Ab2015-11-09Not applicableEu
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
QternDapagliflozin (5 mg) + Saxagliptin (5 mg)TabletOralAstra ZenecaNot applicableNot applicableCanada
QternDapagliflozin (10 mg) + Saxagliptin (5 mg)TabletOralAstra ZenecaNot applicableNot applicableCanada
XigduoDapagliflozin (5 mg) + Metformin Hydrochloride (850 mg)TabletOralAstra Zeneca2016-02-08Not applicableCanada
XigduoDapagliflozin (5 mg) + Metformin Hydrochloride (1000 mg)TabletOralAstra Zeneca2016-02-08Not applicableCanada
Xigduo XRDapagliflozin propanediol monohydrate (2.5 mg/1) + Metformin Hydrochloride (1000 mg/1)Tablet, film coated, extended releaseOralAstra Zeneca Lp2014-10-29Not applicableUs
Xigduo XRDapagliflozin propanediol monohydrate (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coated, extended releaseOralAstra Zeneca Lp2014-11-14Not applicableUs
Xigduo XRDapagliflozin propanediol monohydrate (10 mg/1) + Metformin Hydrochloride (1000 mg/1)Tablet, film coated, extended releaseOralAstra Zeneca Lp2014-11-14Not applicableUs
Xigduo XRDapagliflozin propanediol monohydrate (5 mg/1) + Metformin Hydrochloride (1000 mg/1)Tablet, film coated, extended releaseOralAstra Zeneca Lp2014-11-14Not applicableUs
Xigduo XRDapagliflozin propanediol monohydrate (10 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coated, extended releaseOralAstra Zeneca Lp2014-11-14Not applicableUs
Categories
UNII
1ULL0QJ8UC
CAS number
461432-26-8
Weight
Average: 408.873
Monoisotopic: 408.133966239
Chemical Formula
C21H25ClO6
InChI Key
JVHXJTBJCFBINQ-ADAARDCZSA-N
InChI
InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[[email protected]@H]2O[[email protected]](CO)[[email protected]@H](O)[[email protected]](O)[[email protected]]2O)C=C1

Pharmacology

Indication

Dapagliflozin is indicated for adjunct management of glycemic control in patients with type 2 diabetes mellitus, in combination with diet and exercise.

Structured Indications
Pharmacodynamics

Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin. A Dapagliflozin dose of 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at week 12. A near maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume.

Mechanism of action

A competitive inhibitor of the sodium-glucose transport subtype 2 protein, dapagliflozin blocks glucose reabsorption into the kidney, resulting in the elimination of blood glucose through the urine.

TargetActionsOrganism
ASodium/glucose cotransporter 2
antagonist
Human
Absorption

Cmax is about 1 hour. (Obtained from 6 adult men in a fasted state administered a 50mg dose). 1.6% of unchanged dapagliflozin was found in the urine. A high-fat meal (52% caloric content) had no significant effect on previous pharmacokinetic parameters.

Volume of distribution
Not Available
Protein binding

91%.

Metabolism

Dapagliflozin 3-O-glucuronide is the primary metabolite of dapagliflozin, with 61% of the dapagliflozin dose recovered in the urine as this metabolite. The metabolism of dapagliflozin is primarily mediated by UGT1A9-dependent glucuronide conjugation. The major metabolite, dapagliflozin 3-O-glucuronide, is not an SGLT2 inhibitor.

Route of elimination
Not Available
Half life

13.8 hours with the consumption of a 50 mg dose.

Clearance

Oral plasma clearance of 4.9 mL/min/kg, and a renal clearance of 5.6 mL/min.

Toxicity

Compared to placebo-treated patients, patients with moderate renal impairment treated with dapagliflozin did not have improvement in glycemic control and had more renal-related adverse reactions and more bone fractures; therefore, dapagliflozin should not be initiated in this population. Based on its mechanism of action, dapagliflozin is not expected to be effective in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2) or ESRD.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Dapagliflozin.Experimental
AbirateroneThe serum concentration of Dapagliflozin can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.Approved
AcetaminophenThe serum concentration of Dapagliflozin can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Dapagliflozin.Approved, Vet Approved
AfatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Afatinib.Approved
AlaproclateAlaproclate may increase the hypoglycemic activities of Dapagliflozin.Experimental
AlbendazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.Approved
AldosteroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Dapagliflozin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Dapagliflozin can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.Approved, Investigational
AloxiprinAloxiprin may increase the hypoglycemic activities of Dapagliflozin.Experimental
AmantadineThe serum concentration of Dapagliflozin can be increased when it is combined with Amantadine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Dapagliflozin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dapagliflozin.Approved
Aminohippuric acidThe serum concentration of Dapagliflozin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Dapagliflozin.Approved
AmiodaroneThe metabolism of Dapagliflozin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Dapagliflozin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dapagliflozin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Dapagliflozin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.Approved, Investigational
AmprenavirThe serum concentration of Dapagliflozin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dapagliflozin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Dapagliflozin.Approved
AprepitantThe serum concentration of Dapagliflozin can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Dapagliflozin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Dapagliflozin.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dapagliflozin.Approved, Investigational
ArtemetherThe metabolism of Dapagliflozin can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Dapagliflozin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Dapagliflozin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Dapagliflozin.Approved
AtomoxetineThe metabolism of Dapagliflozin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Dapagliflozin can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Dapagliflozin can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Dapagliflozin.Experimental
BarbitalBarbital may increase the hypotensive activities of Dapagliflozin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Dapagliflozin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dapagliflozin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dapagliflozin.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
BenzocaineThe serum concentration of Dapagliflozin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Dapagliflozin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dapagliflozin.Approved
BiperidenThe serum concentration of Dapagliflozin can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dapagliflozin.Approved
BoceprevirThe metabolism of Dapagliflozin can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Dapagliflozin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dapagliflozin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Dapagliflozin can be increased when it is combined with Bosutinib.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Dapagliflozin.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapagliflozin.Approved
BrofaromineBrofaromine may increase the hypoglycemic activities of Dapagliflozin.Experimental
BromocriptineThe serum concentration of Dapagliflozin can be increased when it is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dapagliflozin.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapagliflozin.Approved, Investigational
BuprenorphineThe serum concentration of Dapagliflozin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Dapagliflozin can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Dapagliflozin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Dapagliflozin can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Dapagliflozin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Dapagliflozin.Approved
CapecitabineThe metabolism of Dapagliflozin can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Dapagliflozin.Approved
CarbamazepineThe metabolism of Dapagliflozin can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Dapagliflozin.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Dapagliflozin.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Dapagliflozin.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dapagliflozin.Approved, Investigational
CaspofunginThe serum concentration of Dapagliflozin can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Dapagliflozin can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Dapagliflozin can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Dapagliflozin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin.Approved, Vet Approved
ChlorpromazineThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dapagliflozin.Approved
CholecalciferolThe metabolism of Dapagliflozin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Dapagliflozin can be increased when it is combined with Cholesterol.Experimental, Investigational
Cholic AcidThe serum concentration of Dapagliflozin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dapagliflozin.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Dapagliflozin.Approved, Investigational
CimetidineThe serum concentration of Dapagliflozin can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Dapagliflozin can be decreased when combined with Cinacalcet.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Withdrawn
CiprofloxacinThe serum concentration of Dapagliflozin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Dapagliflozin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Dapagliflozin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dapagliflozin can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.Approved
ClobazamThe metabolism of Dapagliflozin can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Dapagliflozin.Approved, Investigational
ClofazimineThe serum concentration of Dapagliflozin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Dapagliflozin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.Approved
ClotrimazoleThe metabolism of Dapagliflozin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Dapagliflozin can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Dapagliflozin can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Dapagliflozin can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Dapagliflozin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Dapagliflozin can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe serum concentration of Dapagliflozin can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Dapagliflozin can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Dapagliflozin can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Dapagliflozin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Dapagliflozin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Dactinomycin.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Dapagliflozin.Investigational
DarifenacinThe metabolism of Dapagliflozin can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Dapagliflozin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Dapagliflozin can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Dapagliflozin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dapagliflozin can be decreased when combined with Delavirdine.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Dapagliflozin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapagliflozin.Approved
DesipramineThe serum concentration of Dapagliflozin can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Dapagliflozin can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Dapagliflozin.Approved
DexamethasoneThe serum concentration of Dapagliflozin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapagliflozin.Approved, Vet Approved
DextromethorphanThe serum concentration of Dapagliflozin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Dapagliflozin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Dapagliflozin.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Dapagliflozin.Approved
DigoxinThe serum concentration of Dapagliflozin can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Dapagliflozin can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Dapagliflozin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dapagliflozin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Dapagliflozin can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.Approved
DosulepinThe metabolism of Dapagliflozin can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.Approved
DoxepinThe serum concentration of Dapagliflozin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Dapagliflozin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Dapagliflozin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dapagliflozin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Dapagliflozin can be decreased when combined with Dronedarone.Approved
DuloxetineDapagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfavirenzThe metabolism of Dapagliflozin can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Dapagliflozin.Approved
ElbasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Elbasvir.Approved
EliglustatThe metabolism of Dapagliflozin can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dapagliflozin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dapagliflozin.Approved
EnasidenibThe serum concentration of Dapagliflozin can be increased when it is combined with Enasidenib.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
EnzalutamideThe serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Dapagliflozin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.Approved
ErgonovineThe serum concentration of Dapagliflozin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Dapagliflozin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Dapagliflozin can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.Approved
EstramustineThe serum concentration of Dapagliflozin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Dapagliflozin can be decreased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dapagliflozin.Approved
EtoperidoneEtoperidone may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
EtoposideThe serum concentration of Dapagliflozin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Dapagliflozin can be increased when it is combined with Etravirine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Dapagliflozin.Approved
FentanylThe serum concentration of Dapagliflozin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Dapagliflozin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Dapagliflozin can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Dapagliflozin.Approved, Investigational
FleroxacinFleroxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
FloxuridineThe metabolism of Dapagliflozin can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Dapagliflozin can be decreased when combined with Fluconazole.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
FluorouracilThe metabolism of Dapagliflozin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Dapagliflozin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Dapagliflozin.Approved, Illicit
FlupentixolThe serum concentration of Dapagliflozin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Dapagliflozin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Dapagliflozin can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe metabolism of Dapagliflozin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Dapagliflozin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dapagliflozin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dapagliflozin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dapagliflozin.Approved
FosphenytoinThe metabolism of Dapagliflozin can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Dapagliflozin.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dapagliflozin can be increased when it is combined with Fusidic Acid.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Dapagliflozin.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
GefitinibThe serum concentration of Dapagliflozin can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Dapagliflozin can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
GenisteinThe serum concentration of Dapagliflozin can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Glecaprevir.Approved
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Dapagliflozin.Investigational
GlyburideThe serum concentration of Dapagliflozin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Dapagliflozin can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Dapagliflozin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Dapagliflozin can be increased when it is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Dapagliflozin.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.Approved, Investigational
HaloperidolThe serum concentration of Dapagliflozin can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dapagliflozin.Approved, Vet Approved
HarmalineHarmaline may increase the hypoglycemic activities of Dapagliflozin.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Dapagliflozin.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Dapagliflozin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Dapagliflozin.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dapagliflozin.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dapagliflozin.Approved, Vet Approved
HydrocortisoneThe serum concentration of Dapagliflozin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dapagliflozin.Approved, Investigational
IdelalisibThe serum concentration of Dapagliflozin can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Dapagliflozin.Approved, Investigational
ImatinibThe metabolism of Dapagliflozin can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Dapagliflozin.Investigational
ImipramineThe serum concentration of Dapagliflozin can be increased when it is combined with Imipramine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Dapagliflozin.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Dapagliflozin.Approved
IndinavirThe metabolism of Dapagliflozin can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Dapagliflozin can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Dapagliflozin.Withdrawn
IproclozideIproclozide may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.Approved, Investigational
IsavuconazoniumThe metabolism of Dapagliflozin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Dapagliflozin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dapagliflozin.Approved, Vet Approved
IsoniazidThe metabolism of Dapagliflozin can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dapagliflozin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dapagliflozin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dapagliflozin.Approved
ItraconazoleThe metabolism of Dapagliflozin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dapagliflozin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Dapagliflozin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Dapagliflozin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Dapagliflozin can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dapagliflozin.Approved, Investigational
LansoprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Dapagliflozin can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Dapagliflozin.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dapagliflozin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dapagliflozin.Approved, Investigational
LevodopaDapagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Dapagliflozin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Dapagliflozin.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Dapagliflozin.Approved, Investigational
LevothyroxineThe serum concentration of Dapagliflozin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Dapagliflozin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Dapagliflozin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dapagliflozin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin.Approved, Investigational
LobeglitazoneThe metabolism of Dapagliflozin can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Dapagliflozin.Approved, Investigational
LomitapideThe serum concentration of Dapagliflozin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Dapagliflozin can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Dapagliflozin can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Dapagliflozin can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Dapagliflozin can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Dapagliflozin.Approved
LovastatinThe metabolism of Dapagliflozin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dapagliflozin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Dapagliflozin can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Dapagliflozin can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Dapagliflozin.Approved, Investigational
MaprotilineThe serum concentration of Dapagliflozin can be increased when it is combined with Maprotiline.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
MebendazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.Approved
MefloquineThe serum concentration of Dapagliflozin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Dapagliflozin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Dapagliflozin can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Dapagliflozin.Experimental
MethadoneThe serum concentration of Dapagliflozin can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dapagliflozin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Dapagliflozin.Approved
MethotrimeprazineThe metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dapagliflozin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dapagliflozin.Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Dapagliflozin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dapagliflozin.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dapagliflozin.Approved, Investigational
MexiletineThe metabolism of Dapagliflozin can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Dapagliflozin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Dapagliflozin can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Dapagliflozin can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Dapagliflozin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Dapagliflozin.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Dapagliflozin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dapagliflozin.Approved
MirabegronThe metabolism of Dapagliflozin can be decreased when combined with Mirabegron.Approved
MitomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Dapagliflozin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideMoclobemide may increase the hypoglycemic activities of Dapagliflozin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Dapagliflozin.Approved
MorphineThe serum concentration of Dapagliflozin can be increased when it is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Dapagliflozin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapagliflozin.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Dapagliflozin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
NaltrexoneThe serum concentration of Dapagliflozin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NandroloneNandrolone may increase the hypoglycemic activities of Dapagliflozin.Experimental, Investigational
NaringeninThe serum concentration of Dapagliflozin can be increased when it is combined with Naringenin.Experimental
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dapagliflozin.Approved, Investigational
NefazodoneThe metabolism of Dapagliflozin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dapagliflozin can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Dapagliflozin.Investigational
NeostigmineThe serum concentration of Dapagliflozin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Dapagliflozin.Approved, Investigational
NetupitantThe serum concentration of Dapagliflozin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dapagliflozin can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
NicardipineThe metabolism of Dapagliflozin can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Dapagliflozin.Approved, Investigational
NicotineThe metabolism of Dapagliflozin can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dapagliflozin.Approved
NilotinibThe metabolism of Dapagliflozin can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Dapagliflozin.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dapagliflozin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dapagliflozin.Approved
NitrazepamThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dapagliflozin.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Dapagliflozin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dapagliflozin.Approved
NorethisteroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dapagliflozin.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
OlaparibThe metabolism of Dapagliflozin can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
OmeprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Dapagliflozin can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Dapagliflozin.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dapagliflozin.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Dapagliflozin.Approved, Illicit
P-NitrophenolThe serum concentration of Dapagliflozin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Dapagliflozin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Dapagliflozin can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Dapagliflozin can be increased when it is combined with Palmitic Acid.Approved, Experimental
PanobinostatThe serum concentration of Dapagliflozin can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.Approved
PargylinePargyline may increase the hypoglycemic activities of Dapagliflozin.Approved
ParoxetineThe metabolism of Dapagliflozin can be decreased when combined with Paroxetine.Approved, Investigational
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Dapagliflozin.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
Peginterferon alfa-2bThe serum concentration of Dapagliflozin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Dapagliflozin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Dapagliflozin.Approved, Investigational
PentobarbitalThe metabolism of Dapagliflozin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Dapagliflozin.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Dapagliflozin.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
PhenobarbitalThe metabolism of Dapagliflozin can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dapagliflozin.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Dapagliflozin.Approved
PhenytoinThe metabolism of Dapagliflozin can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Pibrentasvir.Approved
PimozideThe serum concentration of Dapagliflozin can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Dapagliflozin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapagliflozin.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Dapagliflozin.Experimental
PirlindolePirlindole may increase the hypoglycemic activities of Dapagliflozin.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Dapagliflozin.Experimental
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
Platelet Activating FactorThe serum concentration of Dapagliflozin can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Dapagliflozin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Dapagliflozin.Approved, Investigational
PravastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Pravastatin.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.Approved
PrednisoneThe serum concentration of Dapagliflozin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Dapagliflozin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Dapagliflozin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Dapagliflozin can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Dapagliflozin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Dapagliflozin can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dapagliflozin.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Dapagliflozin.Approved, Investigational
ProtriptylineThe serum concentration of Dapagliflozin can be increased when it is combined with Protriptyline.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Dapagliflozin.Investigational
PyrimethamineThe metabolism of Dapagliflozin can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Dapagliflozin can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.Approved
QuinacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Dapagliflozin.Approved, Investigational
QuinidineThe metabolism of Dapagliflozin can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Dapagliflozin can be increased when it is combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dapagliflozin.Approved
RanitidineThe serum concentration of Dapagliflozin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Dapagliflozin can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Dapagliflozin.Approved
ReboxetineThe serum concentration of Dapagliflozin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dapagliflozin.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapagliflozin.Approved, Investigational
RifabutinThe metabolism of Dapagliflozin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dapagliflozin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dapagliflozin can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Dapagliflozin can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Riociguat.Approved
RisperidoneDapagliflozin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Dapagliflozin can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Dapagliflozin can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Dapagliflozin can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapagliflozin.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Dapagliflozin.Approved
RufloxacinRufloxacin may increase the hypoglycemic activities of Dapagliflozin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Dapagliflozin.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Dapagliflozin.Approved, Vet Approved
SaquinavirThe metabolism of Dapagliflozin can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Dapagliflozin can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Dapagliflozin can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Dapagliflozin can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapagliflozin.Approved, Vet Approved
SildenafilThe metabolism of Dapagliflozin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dapagliflozin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Dapagliflozin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Dapagliflozin.Experimental, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Dapagliflozin.Approved
SorafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Dapagliflozin.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.Approved
St. John's WortThe serum concentration of Dapagliflozin can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Dapagliflozin.Approved, Vet Approved
StaurosporineThe serum concentration of Dapagliflozin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Dapagliflozin can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.Approved, Investigational
StreptozocinThe serum concentration of Dapagliflozin can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dapagliflozin.Approved, Investigational
SulfadiazineThe metabolism of Dapagliflozin can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Dapagliflozin can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Dapagliflozin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Dapagliflozin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Dapagliflozin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Dapagliflozin can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Dapagliflozin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Dapagliflozin can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Dapagliflozin.Approved, Investigational
Taurocholic AcidThe serum concentration of Dapagliflozin can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe metabolism of Dapagliflozin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Dapagliflozin can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Dapagliflozin.Withdrawn
TemsirolimusThe serum concentration of Dapagliflozin can be increased when it is combined with Temsirolimus.Approved
Tenofovir disoproxilThe metabolism of Dapagliflozin can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.Approved
TerbinafineThe metabolism of Dapagliflozin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Dapagliflozin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Dapagliflozin can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Dapagliflozin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Dapagliflozin can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapagliflozin.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Dapagliflozin can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Dapagliflozin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Dapagliflozin.Approved, Vet Approved
ThioridazineThe metabolism of Dapagliflozin can be decreased when combined with Thioridazine.Approved, Withdrawn
TicagrelorThe serum concentration of Dapagliflozin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Dapagliflozin can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Dapagliflozin.Approved
TipranavirThe metabolism of Dapagliflozin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.Approved
TocilizumabThe serum concentration of Dapagliflozin can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Dapagliflozin.Approved, Vet Approved
TolbutamideThe metabolism of Dapagliflozin can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapagliflozin.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypoglycemic activities of Dapagliflozin.Approved
TolvaptanThe serum concentration of Dapagliflozin can be increased when it is combined with Tolvaptan.Approved
TopiroxostatThe metabolism of Dapagliflozin can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dapagliflozin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dapagliflozin.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Dapagliflozin.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Dapagliflozin.Approved
TrazodoneThe serum concentration of Dapagliflozin can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Dapagliflozin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.Approved
TrifluoperazineThe serum concentration of Dapagliflozin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Dapagliflozin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Dapagliflozin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Dapagliflozin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Dapagliflozin can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dapagliflozin.Approved, Investigational
VelpatasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Velpatasvir.Approved
VemurafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Dapagliflozin can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Dapagliflozin.Approved
VinblastineThe serum concentration of Dapagliflozin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Dapagliflozin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Dapagliflozin can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Dapagliflozin can be decreased when combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Voxilaprevir.Approved
ZafirlukastThe metabolism of Dapagliflozin can be decreased when combined with Zafirlukast.Approved, Investigational
ZimelidineThe serum concentration of Dapagliflozin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Dapagliflozin can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Dapagliflozin can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

General References
  1. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [PubMed:19996149]
  2. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
  3. Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW: Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x. [PubMed:21226818]
External Links
KEGG Drug
D08897
PubChem Compound
9887712
PubChem Substance
175427068
ChemSpider
8063384
BindingDB
50448923
ChEBI
85078
ChEMBL
CHEMBL429910
Drugs.com
Drugs.com Drug Page
Wikipedia
Dapagliflozin
ATC Codes
A10BD15 — Metformin and dapagliflozinA10BX09 — DapagliflozinA10BD21 — Saxagliptin and dapagliflozin
AHFS Codes
  • 68:20.18 — Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
FDA label
Download (868 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
1CompletedNot AvailableDiabetes / Healthy Male and Female Subjects1
1CompletedNot AvailableType 2 Diabetes Mellitus9
1CompletedBasic ScienceDiabetes, Diabetes Mellitus Type 11
1CompletedBasic ScienceHealthy Volunteers4
1CompletedBasic ScienceType 2 Diabetes Mellitus2
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentType 2 Diabetes Mellitus6
1Enrolling by InvitationTreatmentType1diabetes1
1RecruitingTreatmentType 2 Diabetes Mellitus1
1TerminatedNot AvailableType 2 Diabetes Mellitus1
1TerminatedDiagnosticDiabetes, NOS1
2CompletedBasic ScienceType 2 Diabetes Mellitus1
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentT2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)1
2CompletedTreatmentType 2 Diabetes Mellitus4
2RecruitingBasic ScienceMetabolically Healthy Controls / Type 2 Diabetes Mellitus1
2RecruitingBasic SciencePhysical Activity1
2RecruitingBasic ScienceObese experiencing rapid weight loss2
2RecruitingPreventionBMI >30 kg/m2 / Prediabetic State1
2RecruitingTreatmentAsymptomatic Hyperuricemia1
2, 3Active Not RecruitingTreatmentType 2 Diabetes Mellitus, CKD and Albuminuria / Type 2 Diabetes Mellitus, CKD3 and Albuminuria1
2, 3CompletedTreatmentType 2 Diabetes Mellitus2
3Active Not RecruitingTreatmentDiabetes1
3Active Not RecruitingTreatmentDiabetes Mellitus (DM)1
3Active Not RecruitingTreatmentDiabetes Mellitus, Non-Insulin-Dependent / High Risk for Cardiovascular Event1
3Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
3Active Not RecruitingTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 11
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus2
3CompletedTreatmentCardiovascular Disease (CVD) / Hypertensive / Inadequate Glycaemic Control / Type 2 Diabetes Mellitus1
3CompletedTreatmentCardiovascular Disease (CVD) / Inadequate Glycaemic Control / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes1
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
3CompletedTreatmentHigh Blood Sugar / Type 2 Diabetes Mellitus1
3CompletedTreatmentHigh Blood Sugar / Type2 Diabetes1
3CompletedTreatmentHigh HbA1c Level / Inadequate Glycaemic Control / Type 2 Diabetes Mellitus1
3CompletedTreatmentInadequate Glycaemic Control / Type 2 Diabetes Mellitus / Type2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus22
3Not Yet RecruitingTreatmentType 2 Diabetes Mellitus2
3RecruitingTreatmentBMI >30 kg/m2 / Polycystic Ovaries Syndrome1
3RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentDiabetes Prevention in Women After GDM Who Are at High-risk1
3RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
3RecruitingTreatmentType 2 Diabetes Mellitus3
3SuspendedTreatmentType 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentHyperglycemia Steroid-induced1
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedTreatmentDiabetes / Heart Failure, Unspecified1
4CompletedTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Pre-Diabetic1
4CompletedTreatmentInadequate Glycaemic Control / Type 2 Diabetes Mellitus / Type2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentType 2 Diabetes Mellitus6
4Not Yet RecruitingNot AvailableDiabetes Mellitus (DM) / Hypoglycemic Episodes1
4Not Yet RecruitingBasic ScienceHepatic Glucose Metabolism1
4Not Yet RecruitingBasic ScienceSkeletal Muscle Insulin Sensitivity / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentCarotid Artery Diseases / Coronary Artery Disease / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentDiabetes Mellitus (DM)1
4Not Yet RecruitingTreatmentEvaluate Ketogenic Stress1
4Not Yet RecruitingTreatmentLeft Ventricular Hypertrophy / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentOral Antidiabetics / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentSteatosis, Liver / Type2 Diabetes1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus6
4RecruitingBasic ScienceHypercholesterolaemia / Type 2 Diabetes Mellitus1
4RecruitingBasic ScienceType 2 Diabetes Mellitus1
4RecruitingPreventionDiabetic Nephropathies / Type 2 Diabetes Mellitus1
4RecruitingTreatmentBlood Pressures / BMI >30 kg/m2 / Cardiac Hypertrophy / Hypertensive / Microalbuminuria / Type 2 Diabetes Mellitus / Vascular Stiffness1
4RecruitingTreatmentCardiovascular Disease (CVD) / Type2 Diabetes1
4RecruitingTreatmentChronic Heart Failure With Preserved Systolic Function1
4RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentDiabetes2
4RecruitingTreatmentEndothelial Function / Type 2 Diabetes Mellitus1
4RecruitingTreatmentFasting Glucose / Glucose Excursion / Glycemic Control1
4RecruitingTreatmentGlomerulosclerosis, Focal Segmental1
4RecruitingTreatmentHypertensive / Type 2 Diabetes Mellitus1
4RecruitingTreatmentIschaemic Heart Diseases / Type 2 Diabetes Mellitus1
4RecruitingTreatmentKidney Function Tests / Type 2 Diabetes Mellitus1
4RecruitingTreatmentPre-Diabetic / Prehypertension1
4RecruitingTreatmentType 2 Diabetes Mellitus8
4Unknown StatusTreatmentType 2 Diabetes Mellitus1
4WithdrawnTreatmentType 2 Diabetes Mellitus2
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus1
Not AvailableRecruitingBasic ScienceInsulin Sensitivity / Multiple Mitochondrial Dysfunctions Syndrome1
Not AvailableRecruitingOtherType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableTerminatedNot AvailableType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral10 mg
Tablet, film coatedOral5 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
TabletOral10 mg
TabletOral5 mg
TabletOral
Tablet, film coated, extended releaseOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
USRE44186No2003-07-312023-07-31Us
US8628799No2005-07-132025-07-13Us
US8685934No2010-05-262030-05-26Us
US8501698No2007-06-202027-06-20Us
US6414126No2000-10-042020-10-04Us
US6515117No2000-10-042020-10-04Us
US6936590No2000-10-042020-10-04Us
US9198925No2000-10-042020-10-04Us
US7919598No2009-12-162029-12-16Us
US8361972No2008-03-212028-03-21Us
US8716251No2008-03-212028-03-21Us
US7851502No2008-08-192028-08-19Us
US8221786No2008-03-212028-03-21Us
US9616028No2010-11-122030-11-12Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP2.52ALOGPS
logP2.11ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area99.38 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity104.93 m3·mol-1ChemAxon
Polarizability42.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Phenolic glycosides
Alternative Parents
Diphenylmethanes / Hexoses / C-glycosyl compounds / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Oxanes / Secondary alcohols
show 6 more
Substituents
Phenolic glycoside / Diphenylmethane / Hexose monosaccharide / C-glycosyl compound / Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Aryl chloride
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, organochlorine compound, C-glycosyl compound (CHEBI:85078)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Low-affinity glucose:sodium symporter activity
Specific Function
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
Gene Name
SLC5A2
Uniprot ID
P31639
Uniprot Name
Sodium/glucose cotransporter 2
Molecular Weight
72895.995 Da
References
  1. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [PubMed:19996149]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299]

Drug created on March 19, 2008 10:22 / Updated on November 14, 2017 08:11